Artificial Intelligence to Improve Detection and Risk Stratification of Acute Pulmonary Embolism (AID-PE)
Key facts
- Who runs it
- Royal United Hospitals Bath NHS Foundation Trust
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 3,872 people enrolled
- Started
- 8 Jan 2024
- Ended
- 6 Feb 2025
- Type of study
- Observational, 2 groups
- Treatments tested
- Artificial Intelligence
- Record updated
- 13 February 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Patients over 18 years of age
- Patient requiring CTPA to exclude or diagnose acute PE
Who cannot take part
- Patients under 18 years of age
- Patients who have registered with the national opt-out scheme for research
- CTPA performed for reasons other than acute PE
- CTPA performed for acute PE but reported by external radiologists
- Incomplete or discontinued CTPA scans
- Insufficient quality CTPA to allow for analysis by a radiologist
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this exploratory observational study is to assess the feasibility and real-world clinical impact of implementing Artificial Intelligence (AI) software for the detection of acute Pulmonary Embolism (PE) in patients who undergo Computed Tomography Pulmonary Angiogram (CTPA). The main questions that this study aims to answer are:
Read full original descriptionShow less
[Question 1] What is the real-world impact of AI on the clinical outcomes and decision making by radiologists and clinicians in the management of acute PE?
[Question 2] Is AI software for the detection of acute PE acceptable to use in clinical practice and do they have a favourable impact on clinical workload?
[Question 3] Is it cost-effective to implement AI software for the detection of acute PE in clinical practice?
Patients having a CTPA for the detection of acute PE will have their imaging analysed by AI software in combination with a human radiologist. Researchers will aim to compare the clinical and radiology specific outcomes with a retrospective cohort of patients who have had standard routine radiology reporting.
The 2 groups in the trial
- Prospective Cohort: 'Live' Introduction of AI technology
Consecutive CTPAs, for patients with suspected acute PE, which have their imaging interpreted 'live' by AI technology. The radiologist will have ultimate responsibility for the report generated.
Treatment: Artificial Intelligence
- Comparator Cohort: Standard Radiology reporting
Retrospective CTPAs, for patients with suspected acute PE, which have been reported by a human radiologist only. These CTPAs will not be interpreted by AI technology 'live' BUT undergo analysis to help assess the sensitivity, specificity, false negative, false positive rates of AI technology.
Treatment: Artificial Intelligence
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Developing Artificial Intelligence Solutions to Improve Diagnosis and Risk Stratification in Acute Pulmonary Embolism
- Publications
- Record updated
- 13 February 2025